These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
145 related articles for article (PubMed ID: 38404173)
1. Patient characteristics, treatment patterns, healthcare resource utilization, and costs among patients diagnosed with neurofibromatosis type 1 with and without plexiform neurofibromas in Japan. Yoshida Y; Tozawa K; Koto R; Iwao C; Kim Y; Ban L; Barut V Curr Med Res Opin; 2024 Apr; 40(4):723-731. PubMed ID: 38404173 [TBL] [Abstract][Full Text] [Related]
2. Characteristics, treatment patterns, healthcare resource use, and costs among pediatric patients diagnosed with neurofibromatosis type 1 and plexiform neurofibromas: a retrospective database analysis of a medicaid population. Yang X; Desai K; Agrawal N; Mirchandani K; Chatterjee S; Sarpong E; Sen S Curr Med Res Opin; 2021 Sep; 37(9):1555-1561. PubMed ID: 34218725 [TBL] [Abstract][Full Text] [Related]
3. Treatment, Resource Use and Costs Among Pediatric Patients with Neurofibromatosis Type 1 and Plexiform Neurofibromas. Yang X; Desai K; Agrawal N; Mirchandani K; Chatterjee S; Sarpong E; Sen S Pediatric Health Med Ther; 2020; 11():421-428. PubMed ID: 33117057 [TBL] [Abstract][Full Text] [Related]
4. French cohort of children and adolescents with neurofibromatosis type 1 and symptomatic inoperable plexiform neurofibromas: CASSIOPEA study. Wolkenstein P; Chaix Y; Entz Werle N; Amini-Adle M; Barbarot S; Boileau C; Miled A; Rashid T; Aerts I Eur J Med Genet; 2023 May; 66(5):104734. PubMed ID: 36868501 [TBL] [Abstract][Full Text] [Related]
5. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas. Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379 [TBL] [Abstract][Full Text] [Related]
6. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas. Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781 [TBL] [Abstract][Full Text] [Related]
7. Selumetinib for children with neurofibromatosis type 1 and plexiform neurofibromas: A plain language summary of SPRINT. Gross AM; Achée C; Hart SE; Brewer L; Baldwin A; Wolters PL; Widemann BC; Future Oncol; 2024 May; 20(14):877-890. PubMed ID: 38869947 [TBL] [Abstract][Full Text] [Related]
9. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials. Acar S; Armstrong AE; Hirbe AC Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916 [TBL] [Abstract][Full Text] [Related]
10. Plexiform neurofibroma of the eye region occurring in patients without neurofibromatosis type 1. Bechtold D; Hove HD; Prause JU; Heegaard S; Toft PB Ophthalmic Plast Reconstr Surg; 2012; 28(6):413-5. PubMed ID: 22836801 [TBL] [Abstract][Full Text] [Related]
11. Association of plexiform neurofibroma volume changes and development of clinical morbidities in neurofibromatosis 1. Gross AM; Singh G; Akshintala S; Baldwin A; Dombi E; Ukwuani S; Goodwin A; Liewehr DJ; Steinberg SM; Widemann BC Neuro Oncol; 2018 Nov; 20(12):1643-1651. PubMed ID: 29718344 [TBL] [Abstract][Full Text] [Related]
12. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience. Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293 [TBL] [Abstract][Full Text] [Related]
13. Visual outcomes in children with neurofibromatosis type 1 and orbitotemporal plexiform neurofibromas. Avery RA; Dombi E; Hutcheson KA; Acosta MT; Baldwin AM; Madigan WP; Gillespie A; Fitzgibbon EJ; Packer RJ; Widemann BC Am J Ophthalmol; 2013 Jun; 155(6):1089-1094.e1. PubMed ID: 23453281 [TBL] [Abstract][Full Text] [Related]
14. Response of NF1-related plexiform neurofibroma to high-dose carboplatin. Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936 [TBL] [Abstract][Full Text] [Related]
15. Location, symptoms, and management of plexiform neurofibromas in 127 children with neurofibromatosis 1, attending the National Complex Neurofibromatosis 1 service, 2018-2019. Collins-Sawaragi YC; Ferner R; Vassallo G; De Agrò G; Eccles S; Cadwgan J; Hargrave D; Hupton E; Eelloo J; Lunt L; Tang V; Burkitt Wright E; Lascelles K Am J Med Genet A; 2022 Jun; 188(6):1723-1727. PubMed ID: 35178860 [TBL] [Abstract][Full Text] [Related]
16. The primacy of NF1 loss as the driver of tumorigenesis in neurofibromatosis type 1-associated plexiform neurofibromas. Pemov A; Li H; Patidar R; Hansen NF; Sindiri S; Hartley SW; Wei JS; Elkahloun A; Chandrasekharappa SC; ; Boland JF; Bass S; ; Mullikin JC; Khan J; Widemann BC; Wallace MR; Stewart DR Oncogene; 2017 Jun; 36(22):3168-3177. PubMed ID: 28068329 [TBL] [Abstract][Full Text] [Related]
17. Clinical Characteristics and Management of Children and Adults with Neurofibromatosis Type 1 and Plexiform Neurofibromas in Denmark: A Nationwide Study. Ejerskov C; Farholt S; Nielsen FSK; Berg I; Thomasen SB; Udupi A; Ågesen T; de Fine Licht S; Handrup MM Oncol Ther; 2023 Mar; 11(1):97-110. PubMed ID: 36454436 [TBL] [Abstract][Full Text] [Related]
18. Clinical features of 58 Japanese patients with mosaic neurofibromatosis 1. Tanito K; Ota A; Kamide R; Nakagawa H; Niimura M J Dermatol; 2014 Aug; 41(8):724-8. PubMed ID: 25041723 [TBL] [Abstract][Full Text] [Related]